Capella Columns

RSolv Capella HPLC Columns are the perfect solution for high-performance liquid chromatography applications. Designed to deliver consistent and reliable results, our Capella columns offer exceptional separation efficiency across a diverse range of sample types


RSolv Capella Columns are designed to meet the diverse requirements of analytical and preparative chromatography with a variety of stationary phases:


  • C18: The gold standard for most reverse-phase applications, offering exceptional performance and versatility.
  • C8, C6, C4: Ideal for applications requiring moderate hydrophobic interactions.
  • Phenyl: Tailored for aromatic compounds, providing enhanced selectivity.
  • PFP (Pentafluorophenyl): Perfect for combining polar and hydrophobic interactions.
  • CN (Cyanopropyl):Excels in separating polar compounds and mixtures with high selectivity.
  • AMINO: Specifically suited for basic analytes requiring targeted interactions.
  • DIOL: Optimized for chiral separations and effective across a wide range of compound classes.
  • Silica: Delivers the highest resolution and selectivity for normal-phase chromatography.This comprehensive range ensures precise and efficient separations for a variety of chromatographic applications
product image
Phases Feature
Propyl (C3) Propyl phase separates Polar Compounds, NeutralCompounds and Protein
HTS (C12) Separates biological compounds based on adamantane
Cyclohexyl (C6H12) Separates Aromatic Compounds
Fluorooctyl (C8H16F5) Specifically designed for the separation of fluorinated compounds, isomers and positional isomers combination compounds
Fluoropropyl (C3H6F5) Primarily used for separation of fluorinated compounds

Technical Specifications:


pH Range: 2.0-8.0


Pore Size: 60Å, 100Å, 125Å(Custom Req),300Å


Particle Size (μm): 1.8 (Length: 30 to 150), 3.0, 5.0,10.0 (Length: 50 to 250)


Surface area: 325 m²/g


Length: 30, 50, 100, 150 and 250


Dimension: 2.1, 3.0, 4.0 and 4.6


Application: Tazobactum, Rufinamide, Sulfadiazine, Tafamidis meglumine and Acalabrutinib


product image